Prophytaxie de l'ostéoporose cortisonique: qui, quand et quoi [Prevention of cortisone-induced osteoporosis: who, when and what?]

Details

Serval ID
serval:BIB_14DB30821BE6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prophytaxie de l'ostéoporose cortisonique: qui, quand et quoi [Prevention of cortisone-induced osteoporosis: who, when and what?]
Journal
Revue Médicale Suisse
Author(s)
Aubry-Rozier B., Lamy O., Dudler J.
ISSN
1660-9379[print], 1660-9379[linking]
Publication state
Published
Issued date
2010
Volume
6
Number
235
Pages
307-313
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Glucocorticoid-induced osteoporosis is a known phenomenon with already an increased fracture risk at 2.5 mg of prednisone daily over 3 months. This risk appears to be independent of bone densitometry results, in contradiction with published guidelines. With the creation of our Department of Musculoskeletal Medicine, we wanted to edict clear recommendations for the prevention of steroid-induced osteoporosis. In addition to the standard general measures to prevent osteoporosis and calcium and vitamin D supplementation, we advocate the use of a specific treatment for osteoporosis in all cases when the duration of corticosteroid therapy is not strictly limited and shorter than 3 months. Bisphosphonates are the treatment of choice, while the analogue of parathyroid hormone remains an alternative in cases with a very high fracture risk.
Keywords
Aged, Aged, 80 and over, Aging, Anti-Inflammatory Agents/administration & dosage, Anti-Inflammatory Agents/adverse effects, Cortisone/administration & dosage, Cortisone/adverse effects, Drug Administration Schedule, Fractures, Bone/epidemiology, Fractures, Bone/prevention & control, Humans, Middle Aged, Osteoporosis/chemically induced, Osteoporosis/prevention & control
Pubmed
Create date
28/06/2010 17:44
Last modification date
20/08/2019 13:43
Usage data